middle.news
Orthocell’s Remplir Achieves 81% Success in Real-World Nerve Repair Study
9:13am on Monday 8th of September, 2025 AEST
•
Healthcare
Read Story
Orthocell’s Remplir Achieves 81% Success in Real-World Nerve Repair Study
9:13am on Monday 8th of September, 2025 AEST
Key Points
81.1% overall treatment success rate in nerve repair procedures
No adverse reactions or complications reported in 67 procedures
Over 200 surgeons across 165 hospitals currently using Remplir
Supports US market rollout and upcoming EU/UK regulatory submissions
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ORTHOCELL (ASX:OCC)
OPEN ARTICLE